ARTICLE | Clinical News
Glenmark's revamilast misses RA endpoint
February 2, 2013 2:00 AM UTC
Glenmark Pharmaceuticals Ltd. (NSE:GLENMARK; BSE:532296) disclosed in its third quarter earnings for the fiscal year ending March 31, 2013, that revamilast missed the primary endpoint of improving ACR...